Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the ...

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat reports.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), ...

Proficio Capital Partners LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) during the fourth ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

San Francisco's Montara Therapeutics secures $20 million in seed funding to advance epilepsy drug development and explore partnerships, led by biotech veterans.

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

United Therapeutics Corporation , a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's ...

LGT Fund Management Co Ltd. acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...